In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

1 Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 ... The discovery that global muscle hypertrophy has anti-obesity and anti-diabetic effects prompts critical ...

One of the therapeutic drugs for T2DM, dipeptidyl peptidase-4 (DPP-4) inhibitor, suppresses the degradation of incretins, glucagon-like peptides and glucose-dependent insulinotropic ... increase the ...

Obesity and diabetes are ... such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are additionally utilized or are under consideration ...

Background: Despite their potential, Glucagon-like peptide ... 1 RA. Patients were assessed at follow-up periods of 1 month and 1 year. Propensity score-matched analysis (PSM) (1:1) was performed with ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...